Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus gemcitabine + cisplatin as neoadjuvant and durvalumab as adjuvant therapy in muscle‑invasive bladder cancer
jRCT2080224149Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of durvalumab in muscle-invasive bladder carcinoma (MIBC) (2 arms), sponsored by AstraZeneca. Started Nov 2018; status: completed.
02
Drugs
durvalumab
03
Conditions
muscle-invasive bladder carcinoma (MIBC)
Beyond the preview
Go deeper on jRCT2080224149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224149.